Esperion Therapeutics, Inc. Business Operations Contracts & Agreements
12 Contracts & Agreements
- Collaboration Agreements (6 contracts)
- Indemnification Agreements (2)
- MOUs (1)
- Sales Agreements (1)
- Services Agreements (1)
- Termination Agreements (1)
- Controlled Equity OfferingSM Sales Agreement, by and between Esperion Therapeutics, Inc. and Cantor Fitzgerald & Co., dated February 21, 2023 (Filed With SEC on February 21, 2023)
- License and Collaboration Agreement, by and between the Registrant and Daiichi Sankyo Company, Limited dated April 26, 2021 (Filed With SEC on August 3, 2021)
- 2nd Amendment to the License and Collaboration Agreement by and between the Registrant and Daiichi Sankyo Europe GMBH dated March 19, 2021 (Filed With SEC on May 4, 2021)
- 1st Amendment to the License and Collaboration Agreement by and between the Registrant and Daiichi Sankyo Europe GMBH dated June 18, 2020 (Filed With SEC on August 10, 2020)
- License and Collaboration Agreement by and between the Registrant and Otsuka Pharmaceutical Co., Ltd. dated April 17, 2020 (Filed With SEC on August 10, 2020)
- License and Collaboration Agreement by and between Daiichi Sankyo Europe GmbH and the Company, dated as of January 2, 2019 (Filed With SEC on February 28, 2019)
- TERMINATION AGREEMENT (Filed With SEC on December 3, 2015)
- ESPERION THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT (Filed With SEC on May 14, 2013)
- ESPERION THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT (Filed With SEC on May 14, 2013)
- Amendment to Collaboration & License Agreement (Filed With SEC on December 23, 2003)
- EX-10.55 Advisory Services Agreement (Filed With SEC on August 14, 2003)
- Memorandum of Understanding (Filed With SEC on March 14, 2002)
